Pharma Industry News
A collection of Pharma latest news, analysis and best practices from top business influencers and the world's most trustworthy sources.
Nxera Pharma Operational Highlights and Consolidated Results for the Fourth Quarter and Full Year 2025
Tokyo, Japan and Cambridge, UK, 13 February 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) provides an update on operational activities and reports its consolidated results for the fourth…
Nxera Pharma to Receive $1.8 Million Milestone Payment from Centessa Pharmaceuticals
Tokyo, Japan and Cambridge, UK, 12 February 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today notes that Centessa Pharmaceuticals has achieved an early development milestone associated with…
Lantern Pharma (LTRN) Advances Oncology AI and Gains Orphan Drug Recognition
Lantern Pharma, Inc. (NASDAQ: LTRN) is one of the best AI penny stocks to buy right now. On January 20, the FDA granted Lantern Pharma, Inc.'s (NASDAQ:LTRN) LP-284 an Orphan Drug Designation (ODD). LP-284 is an investigational small-molecule…
Nxera Pharma Licenses GPCR-targeted Program to Newly Founded Spin-out Company
New company established by a leading international life sciences investment firm Tokyo, Japan and Cambridge, UK, 12 January 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announced that it has…
Zealand Pharma conference call on February 19 at 2pm CET (8am ET) to present full year 2025 financial results
Press Release – No. 3 / 2026 Zealand Pharma conference call on February 19 at 2pm CET (8am ET) to present full year 2025 financial results Copenhagen, Denmark, February 12, 2026 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078)…
Uttar Pradesh govt's pharma investment kitty hits ₹38,000 crore
While 210 investment proposals to the tune of ₹28,000 cr were received following the Uttar Pradesh Global Investors' Summit (GIS) in 2024, the state secured about a dozen fresh investment proposals at the UP Pharma Conclave in Lucknow…
Ascentage Pharma Group International (AAPG) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 Transcript
Ascentage Pharma Group International (AAPG) Guggenheim Securities Emerging Outlook: Biotech Summit 2026 February 12, 2026 9:30 AM EST Veet Misra - Chief Financial Officer Bradley Canino - Guggenheim Securities, LLC Here at the Guggenheim…
Exclusive - Secretary Lutnick: $400 Billion of Pharma Manufacturing Coming Home to America
Four hundred billion dollars of pharmaceutical manufacturing is headed to the U.S. thanks to the Trump administration's policies, Commerce Secretary Howard Lutnick said Wednesday at a policy discussion hosted by Breitbart News. “We're gonna…
From Philosophy to Pharma: Meet UC San Diego Skaggs School of Pharmacy Alum Courtney Shakowski
Courtney Shakowski, PharmD, '11, was always drawn to the sciences, but after tragically experiencing the Columbine High School shooting she changed her college major to philosophy. Recognizing her blend of STEM talent and curiosity…
Europe's machinery and pharma strengths give leverage over US and China, report finds
Europe's hold over machines, pharmaceuticals and other products in global supply-chains give leverage over the United States and China, according to a report published Friday (13 February), ahead of the Munich Security Conference. The study…
NATCO Pharma Q3 PAT up
NATCO Pharma has posted a net profit of ₹151.3 crore in the third quarter ended December 31, 2025, as against ₹132.4 crore in the comparable quarter last year. It registered a revenue of ₹647.30 crore (₹475 crore) in the…
Natco Pharma consolidated net profit rises 13.91% in the December 2025 quarter
Last Updated: Feb 12 2026 | 4:11 PM IST Sales rise 36.33% to Rs 647.30 crore Net profit of Natco Pharma rose 13.91% to Rs 151.50 crore in the quarter ended December 2025 as against Rs 133.00 crore during the previous quarter ended December 2024.
Ex-Pharma Exec Fights AGs' Quick Win Bid In Antitrust Case
A former pharmaceutical marketing executive urged a Connecticut federal court to reject summary judgment sought against him by state attorneys general pursuing wider price-fixing litigation against most of the generic drug... To view the full…
'Not an exit': Founder says USV deal signals pharma validation for nutraceuticals
The sale of 79 per cent stake for a consideration of ₹1,583 crore in Wellbeing Nutrition to pharma major USV is not a founder exit but a strategic partnership to scale within a pharmaceutical ecosystem, according to Avnish Chhabria, Founder…
Ascendis Pharma A/S (NASDAQ:ASND) Given Consensus Rating of 'Buy' by Brokerages
Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) has been assigned a consensus recommendation of 'Buy' from the seventeen ratings firms that are presently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with…
Receive a Daily briefing on Pharma Industry News
Get Started